Member Info for Matml74

That all ties in with RM in his last interview and reference to P2/early data and EUA. There is real potential here for EUA to be granted in March!

Ahh tiptree. That makes more sense..... BBC are ****in useless.

jaffjoon, Really? Copywriter must have screwed up.

Taverham, BBC are a disgrace. Their journalists are brain dead. I got some lip service from them when complaining about the botox doctor commenting on our P3 trial start. Their pathetic response and justification for using her comments ensured they won't be getting my licence fee when it becomes due.

Well put Hydro.

This guy is just Greenfool reincarnate. I will stick with GGP/Newcrest and analysts opinions with particular focus with what the CEO said yesterday.

Two things stood out in the ODD rns that continue to point us towards avacta’s LFD being the one..::

Revenue from COVID-19 activities is expected to be approximately £1.5 million which includes sales from the UK-RTC antibody test, sales of the Mologic ELISA antibody test and development income for work undertaken on behalf of a third party.

....... so the third party work relates to Avactas test! We know they we working on it.

“
The intention is that as soon as the DHSC has access to a test that has successfully passed a performance evaluation, the test will be licensed for Omega to manufacture.”

So they still don’t have a validated test yet to produce.......... but one is coming!

Awesome. Yanks get it. Can't believe we haven't had anyone in the UK from the powers that be even mention this!

Nice mention here .....

https://www.dw.com/en/a-look-at-promising-treatments-for-covid-19/av-56526916

Certainly gets the brain started up Oak!

More on interferons for use in targeted therapy for coronaviruses. SNG highlighted for targeted treatment in early stages.

https://www.nature.com/articles/s41392-021-00480-z

Trading, Interim results are published 25th March. I would expect a trading update at that point on any significant sales that have occurred after the result period.

Next RNS should be the POC launch to market.

A £350k trade went through in the middle of the day at 175 so seems an mm is still working an order.

I have seen the data that Joey is referring to. Just under 90m shares in the hands of PI's. A number of institutions and long term PI's with large holdings under the 3% threshold.

The risk of a successful clinical validation still exists. Until the market sees that risk removed the big move north won't occur. Hopefully the validation occurs by end of the month.

It's not continuing to drop. It is trading in a range from 23p-29p and has been since 18th Jan. There is substantial buying in the low 20's hence the support at around 23p.

The mm's could try a drop into the teens on poor scallywag results but it won't stay there for long as there would be rampant buying. I'd be selling my children to get more shares below 20p as would many others I expect!

No problems Mike. We would all like to know what is going on with the P3 and get more regular updates. I would really like to know where we are in manufacturing of the drug etc. That would really tell us where we are headed I think. As you will well know having been here so long we just have to trust the BOD that this is all getting done. They haven't let us down to date.

Fair enough Mike. Apologies.

Mike it has always been like that. Every trial. You get a first patient dosing and a last patient dosed. Don't expect anything in between. If you want an RNS every week then this stock is not the right place to be.

RNS's to expect over then 2-4 months
Fist patient dosed Activ-2
Home trial results
Activ 2 move to P3 of Activ trial
P3 last patient dosed
P3 results

Outside chances for RNS

Manufacturing update
EUA
Partner agreement

Alpha, Many of the dots surrounding interferon and covid are now joined up. The science is comprehensive. These are just snippets of papers form the past month!

- But this latest research shows that it is predominantly the short ACE2, which lacks the viral binding site, that is increased in response to interferons. Since levels of the longer form of ACE2 remain unchanged, interferons do not appear to boost entry points for the virus, supporting their use in treating COVID-19 patients. (Southampton Uni 2021)
- Structural Variations in IFNAR1 that Correlate with COVID-19 Severity (Rockafella 2021)
-Higher levels of type I interferons, as well as the induction of trained immunity and local mucosal immunity also contribute to lower risk of infection (Pathogen paper 2021).
- Demonstration that SARS-CoV-2 is able to inhibit RIG-I mediated IFN-b production. (Sweden 2021)
- Understanding of the immunobiology of COVID-19 have provided key insights into the centrality of interferons in the immune response against severe acute respiratory syndrome coronavirus (Lancet Rheumatology paper 2021)

The world's drug governing bodies need to pull their fingers out of their preverbal and follow the science. They provided EUA based on a benefit vs risk basis for vaccines. They need to apply the same principle now towards interferon treatments. Too many lives are being needlessly lost!

It is coming....

https://www.brisbanetimes.com.au/national/queensland/researchers-identify-gene-that-gives-early-warning-of-severe-covid-19-20210208-p570na.html